Pardes Biosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PRDS research report →
Price Chart
About the company
Pardes Biosciences, Inc. is a clinical-stage biopharmaceutical firm dedicated to identifying, developing, and marketing groundbreaking treatments. The company's core objective is to improve outcomes for patients battling life-threatening illnesses.
- CEO
- Thomas G. Wiggans
- IPO
- 2021
- Employees
- 57
- HQ
- Carlsbad, CA, US
Get TickerSpark's AI analysis on PRDS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $135.19M
- P/E
- -1.35
- PEG
- -2.78
- P/S
- 0.00
- P/B
- 0.70
- EV/EBITDA
- -0.81
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -41.86%
- ROIC
- -53.57%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-99,817,000
- Net Income
- $-93,451,000-142.4%
- EPS
- $-1.61-136.8%
- OCF Growth
- -95.0%
- FCF Growth
- -95.0%
- 52W High
- $3.67
- 52W Low
- $0.75
- 50D MA
- $2.03
- 200D MA
- $1.70
- Beta
- 0.42
- RSI (14)
- 70
- Avg Volume
- 509.69K
No earnings-call transcripts are available for PRDS yet.
- Free Float
- 22.7%
- Shares Outstanding
- 62.01M
- Float Shares
- 14.06M
of shares held by institutions
59 13F filers
Buy/sell ratio 0.10. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Foresite Capital Opportunity Management V, LLC | 5.23M | 0 |
| American Portfolios Advisors | 1.00K | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 31, 23 | Tananbaum James B. | other | 1,000 |
| Aug 31, 23 | Tananbaum James B. | sell | 37,500 |
| Aug 31, 23 | Tananbaum James B. | sell | 75,000 |
| Aug 31, 23 | Tananbaum James B. | sell | 16,813,146 |
| Aug 31, 23 | Tananbaum James B. | sell | 37,500 |
| Aug 31, 23 | WIGGANS THOMAS G | other | 50,000 |
| Aug 31, 23 | WIGGANS THOMAS G | sell | 562,500 |
| Aug 31, 23 | WIGGANS THOMAS G | sell | 985,000 |
| Aug 31, 23 | WIGGANS THOMAS G | sell | 450,000 |
| Aug 31, 23 | Varney Michael David | sell | 37,500 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PRDS coverage
Recent articles, reports, and earnings notes.
No research on PRDS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PRDS report →Pardes Biosciences Announces Closing of Tender Offer
globenewswire.com · Aug 31
MediPacific Offering $2.13 Per Share Plus One Contingent Value Right Per Share in Tender Offer for Pardes Biosciences
businesswire.com · Aug 28
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
accesswire.com · Aug 19
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
accesswire.com · Aug 18
MediPacific Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Pardes Biosciences Shares
businesswire.com · Aug 17
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
accesswire.com · Aug 9
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
accesswire.com · Aug 8
PARDES BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pardes Biosciences, Inc. - PRDS
businesswire.com · Aug 7
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.